New combo therapy for rare breast cancer type shows early safety focus
NCT ID NCT04504331
First seen Feb 17, 2026 · Last updated Apr 30, 2026 · Updated 6 times
Summary
This early-phase study tested a new drug (infigratinib) combined with tamoxifen in people with a specific advanced breast cancer (hormone receptor-positive, HER2-negative, with FGFR gene changes). The main goal was to find a safe dose and check for side effects. Only 4 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94304, United States
Conditions
Explore the condition pages connected to this study.